Results 171 to 180 of about 160,832 (337)
Fatal Tumor Lysis Syndrome Induced by Pembrolizumab in Advanced Renal Pelvis Cancer
ABSTRACT Introduction Tumor lysis syndrome (TLS) arises from the rapid breakdown of tumor cells during oncological treatment. Although TLS is rarely observed in solid tumors, few studies have documented instances of TLS associated with pembrolizumab. This report presents a case involving pembrolizumab‐induced TLS.
Takashi Asakura +3 more
wiley +1 more source
Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study) [PDF]
Hideaki Takahashi +19 more
openalex +1 more source
ABSTRACT Introduction Doege–Potter syndrome (DPS) is a rare paraneoplastic phenomenon of severe hypoglycemia associated with solitary fibrous tumors (SFT). We report a case of a giant pelvic SFT with DPS, which was managed with preoperative arterial embolization and complete excision.
Rei Narimatsu +9 more
wiley +1 more source
ABSTRACT Introduction Enfortumab vedotin (EV), a Nectin‐4–targeted antibody–drug conjugate, is active in previously treated urothelial carcinoma. Cavitation of pulmonary metastases is classically linked to squamous histology or anti‐angiogenic/cytotoxic regimens; rarely reported under EV.
Fumihiro Ito +4 more
wiley +1 more source
Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III Non-small Cell Lung Cancer [PDF]
Qian Chen +5 more
openalex +1 more source
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto +6 more
wiley +1 more source
Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. [PDF]
Barajas J +5 more
europepmc +1 more source

